Table 1 EC50s of compounds against tested Trypanosoma cruzi strains and clones

From: Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development

 

Dm28c

Y

ARMA13 cl1

ERA cl2

92-80 cl2

CL Brener

Tulahuen

 

DTU I

DTU II

DTU III

DTU IV

DTU V

DTU VI

DTU VI

Benznidazole

2.5 × 10−6

2.4 × 10−6

7.3 × 10−7

1.1 × 10−6

7.0 × 10−7

1.6 × 10−6

6.3 × 10−7

Nifurtimox

1.5 × 10−6

1.4 × 10−6

1.9 × 10−7

2.3 × 10−7

1.9 × 10−7

3.5 × 10−7

2.4 × 10−7

Fexi. Sulfone

7.5 × 10−6

1.1 × 10−5

1.9 × 10−6

2.4 × 10−6

1.4 × 10−6

1.3 × 10−6

3.0 × 10−6

AN4169

3.7 × 10−7

4.4 × 10−7

2.1 × 10−7

2.8 × 10−7

1.5 × 10−7

1.9 × 10−7

2.8 × 10−7

Posaconazole

5.3 × 10−9

1.1 × 10−8

-

9.1 × 10−9

-

1.2 × 10−9

1.0 × 10−9

Ravuconazole

3.6 × 10−9

1.1 × 10−9

8.7 × 10−10

2.2 × 10−9

-

7.4 × 10−10

6.2 × 10−10

EPL-BS967

2.2 × 10−8

1.8 × 10−7

-

8.2 × 10−9

1.0 × 10−7

-

5.2 × 10−8

EPL-BS1246

2.7 × 10−7

6.1 × 10−8

-

1.4 × 10−7

6.1 × 10−7

2.1 × 10−8

1.9 × 10−8

  1. All values refer to compound molarity (M); in cases denoted by “-”, the maximum activity of the compound was below 50% at the highest concentration tested and thus EC50s could not be determined; see also Table 2. Data obtained from at least two independent experiments.